about
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis.A new hypothesis on the role of c-erbB2 oncogene in the progress of breast cancerMorphofunctional analysis of experimental model of esophageal achalasia in ratsThe value of the preoperative FISH test in unscreened bladder cancer patients with TUR indications
P50
Q34603290-356B3ABC-0118-49CC-BE7D-B105A34F5DC8Q36649978-8EE5E061-E2B8-47B7-817E-068265429B9FQ37532641-70F9FC90-D3D8-4DE8-B21E-A381C994F026Q42882393-1BACE67A-7A6B-48E4-8EE5-7D9006267415Q46736552-9BA4591A-58C2-4433-8BCF-BFD02B6C2313Q48045606-A1872C63-A8A1-42D7-BAAE-A7868E9940ECQ50856830-B10ED4B5-3FD6-4A24-B897-AE654A4F3155Q79977070-BD80FB3E-EB8A-4CE8-BEFB-C533345FC592Q83203896-A30DD9F8-9C85-4C5B-BF85-192EE7AC033DQ84449498-86E12DEB-D1C8-451F-B45C-D7B5CF06936C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
R Khasanov
@ast
R Khasanov
@en
R Khasanov
@es
R Khasanov
@nl
type
label
R Khasanov
@ast
R Khasanov
@en
R Khasanov
@es
R Khasanov
@nl
prefLabel
R Khasanov
@ast
R Khasanov
@en
R Khasanov
@es
R Khasanov
@nl
P106
P1153
15048020700
P31
P496
0000-0003-4107-8608